Indivior's Record Q3 Earnings Set the Stage for Supernus Merger

RICHMOND, Va. – October 29, 2026 – In what marks its final financial dispatch as an independent entity, Indivior Pharmaceuticals delivered a resounding third-quarter performance, characterized by surging revenues, dramatic margin expansion, and a decisive restructuring of its operational footprint. The company reported a 13% year-over-year increase in total net revenue, reaching $356 million, alongside a 76% explosion in adjusted EBITDA to $211 million.

Beyond the raw financial metrics, these results represent the culmination of the "Indivior Action Agenda," a strategic overhaul designed to maximize the value of its core addiction treatments while preparing the organization for its imminent, transformative all-stock merger with Supernus Pharmaceuticals. Scheduled to close on November 2, the combination will create a diversified central nervous system (CNS) powerhouse trading under the ticker symbol SUPN.

For observers of institutional healthcare innovation, Indivior's trajectory offers a compelling case study in how targeted clinical focus can align with aggressive corporate restructuring to drive both shareholder value and community health outcomes.

The SUBLOCADE Engine and Community Impact

The undisputed engine of Indivior's Q3 success is SUBLOCADE, the company's long-acting injectable buprenorphine treatment for opioid use disorder (OUD). The franchise posted record net revenues of $267 million for the quarter, a 22% increase year-over-year, driven largely by a 17% growth in U.S. dispense unit volume. Since its launch, over 583,000 patients in the U.S. have been prescribed the medication.

The clinical and societal implications of this growth cannot be overstated. For decades, the frontline treatment for OUD relied heavily on daily oral medications. While effective, these regimens often present significant adherence challenges for vulnerable populations and carry inherent risks of medication diversion. Long-acting injectables represent a paradigm shift in addiction medicine, offering patients a month of stable medication levels. This innovation provides a foundation of physiological stability, allowing individuals to focus on the behavioral and social aspects of their recovery with greater independence and dignity.

"In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda," said Joe Ciaffoni, Chief Executive Officer. "Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda."

Decoding the Dramatic Cost Cuts

While top-line growth was robust, the most striking element of Indivior's Q3 report is the sheer scale of its expense reduction. GAAP operating expenses plummeted by 33% year-over-year, dropping from $187 million in Q3 2025 to $125 million in Q3 2026.

This leaner operational profile is the direct result of aggressive portfolio prioritization. Over the past year, Indivior made the calculated decision to discontinue sales and marketing support for OPVEE (an opioid overdose reversal agent) and PERSERIS (a long-acting injectable for schizophrenia). By shedding these assets, the company eliminated significant commercial and administrative overhead.

However, the most scrutinized line item will undoubtedly be research and development. R&D spending was slashed from $33 million in the third quarter of 2025 to a mere $5 million in Q3 2026. While this precipitous drop effectively boosted short-term profitability—pushing the adjusted EBITDA margin up 2,100 basis points to an impressive 59%—it raises critical questions about organic pipeline depth.

Critics might argue that Indivior maximized short-term deal value at the expense of its own future innovation. Yet, from a strategic standpoint, this severe trimming was likely a necessary maneuver to "dress the bride" for the Supernus merger. By stripping away peripheral costs and focusing entirely on the highly profitable SUBLOCADE franchise, Indivior presented a financially pristine asset to its merger partner, trusting that the combined entity will possess the scale to fund future R&D endeavors across a broader CNS spectrum.

Balance Sheet Shifts and the Billion-Dollar Payout

The financial mechanics facilitating the Supernus merger are as complex as they are lucrative for existing shareholders. Indivior ended the quarter with $332 million in cash and investments, a strong liquidity position noted by Chief Financial Officer Ryan Preblick.

"Our strong results and the execution of our Indivior Action Agenda puts us on track to achieve our previously communicated 2026 financial guidance, excluding the impact of our pending acquisition," Preblick stated, emphasizing the cash generation that adds to the financial strength of the incoming merger.

But the balance sheet also reveals the structural preparations for a massive capital return. Indivior's condensed consolidated balance sheet shows a sudden reclassification of $488 million into current long-term debt, alongside an $18 million loss on debt extinguishment for the nine months ended September 30.

These movements are directly tied to the financing of a $1.0 billion special cash dividend—amounting to $8.13 per share—declared for Indivior shareholders, contingent upon the merger's closing. To fund this massive payout, the company secured a new $650 million senior secured term loan facility from Citibank. The debt extinguishment losses and the reclassification of liabilities reflect the retiring of old credit facilities and the onboarding of this new debt structure. It is a bold financial engineering move that rewards Indivior's legacy investors while effectively transferring a leveraged, yet highly cash-generative, balance sheet to the new Supernus, Inc.

Beyond Opioid Addiction: A New Era in CNS Care

When the opening bell rings on November 3, the standalone Indivior will cease to exist, replaced by a newly scaled Supernus, Inc. Under the terms of the "merger of equals," Indivior stockholders will own approximately 56.5% of the combined company, with Supernus stockholders holding the remainder. The new entity will be helmed by current Supernus President and CEO Jack Khattar, with Indivior board member Tony Kingsley serving as Chair.

The strategic logic of this tie-up extends far beyond financial synergies, which are projected to reach $125 million annually by the end of 2027. By pairing Indivior's dominant addiction medicine franchise with Supernus's established portfolio of treatments for ADHD, Parkinson's disease, and depression, the combined company instantly diversifies its revenue streams. It mitigates the inherent regulatory and market risks of relying solely on opioid use disorder treatments while creating a comprehensive CNS portfolio comprising 11 commercial medicines.

For the broader healthcare community, this consolidation represents a formidable new player with pro forma net revenues of approximately $2.2 billion. The true test of this merger will not just be in realizing cost synergies or managing the new debt load, but in whether this newly scaled institution can leverage its combined resources to drive meaningful innovation. As mental health and addiction increasingly intersect in our communities, a corporate entity equipped to address both with long-acting, evidence-based therapeutics has the potential to profoundly shape the future of shared wellbeing.